Table 1 Characteristics of the included RCTs.
Trial | Area | Trial period | Medication | Male/female | Age | Type of migraine |
|---|---|---|---|---|---|---|
NCT0262986123 | North America and Europe | 2016 to 2017 | Fremanezumab 225 mg monthly | 46/244 | 42.9 | Episodic |
Fremanezumab 675 mg single high dose | 40/251 | 41.1 | ||||
Placebo | 47/247 | 41.3 | ||||
NCT0262193125 | North America | 2016 to 2017 | Fremanezumab 675 mg + 225 mg*2 | 49/330 | 40.6 | Chronic |
Fremanezumab 675 mg single high dose | 45/331 | 42.0 | ||||
Placebo | 45/330 | 41.4 | ||||
North America | 2014 | Fremanezumab 900 mg*3 | 12/75 | 41.5 | Chronic | |
Fremanezumab 675 + 225 mg*2 | 12/76 | 40.0 | ||||
Placebo | 13/76 | 40.7 | ||||
NCT0202555652 | North America | 2014 to 2015 | Fremanezumab 675 mg*3 | 15/82 | 40.7 | Episodic |
Fremanezumab 225 mg*3 | 9/87 | 40.8 | ||||
Placebo | 12/92 | 42.0 | ||||
NCT0330896827 | North America and Europe | 2017 to 2018 | Fremanezumab 225 mg*3/675 mg + 225 mg*2 | 45/238 | 45.9 | Episodic or chronic |
Fremanezumab 675 mg single high dose | 47/229 | 45.8 | ||||
Placebo | 46/233 | 46.8 |
